Interestingly, each of the four mutants M1–M4 exhibited defective capacity to inhibit tumor growth as compared to WT SMARCB1 (Fig. 1i and Supplementary Fig. S9g), indicating that these mutants have lost, at least in part, their tumor-suppressive activity. This evidence concerns the gene SMARCB1 and neoplasm.